Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.


Cardior’s lead compound against heart failure demonstrates excellent tolerability and safety

Ascenion’s portfolio company Cardior Pharmaceuticals announced positive results of a Phase Ib study with its first-in-class compound CDR132L.

The compound is an antisense oligonucleotide inhibiting certain micro-RNAs in heart tissue that regulate the pathological growth of heart muscle cells. In the trial, CDR132L met all endpoints and showed excellent tolerability and safety. The infusion was very well tolerated by all patients, and no safety signals or unexpected adverse events were observed. Moreover, PK data showed strong dose-dependent linearity and specific target engagement could be confirmed. These data further support the potential of RNA-based therapies as a causal approach to treat heart diseases.

Further information: